LLY · News · 20260923N

Product / Drug Pipeline Progress - retatrutide

ELI LILLY & Co · 2026-09-23 · Importance 31 · Surprise 42

Eli Lilly’s next-generation obesity medicine retatrutide generated strong results in Phase 3 studies. The program strengthens Lilly’s obesity-drug pipeline beyond currently marketed GLP-1 products. Retatrutide could become a future commercial product in the company’s core metabolic-therapy area.

Key facts

• Eli Lilly's next-gen obesity drug retatrutide posted excellent results in Phase 3 studies. source